Abstract
肺癌是最常见和死亡率最高的恶性肿瘤之一，75%-80%为非小细胞肺癌（non-small cell lung cancer, NSCLC）。且绝大部分患者就诊时已处晚期，失去了根治性手术或放疗的机会，化疗是主要的治疗手段。但由于肿瘤生物学行为的多样性和对化疗药物的耐药等，使得晚期NSCLC的化疗不容乐观。近年来，分子标志物的个体化化疗在晚期NSCLC的应用，使得这些患者生存期有所延长，生活质量有所提高。针对晚期NSCLC，根据分子标志物选择合适的药物，达到个体化化疗是临床中所要面对和解决的问题。本文就核苷酸还原酶M1（ribonucleotide reductase subunit 1, RRM1）在晚期NSCLC治疗和预后中的作用做一简要综述。由RRM1指导的个体化化疗并不能作为晚期NSCLC的常规决策，还需进一步研究。
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
